Since its founding in 2010. Oncotarget has carved out a name for itself as one of the leading peer-reviewed journals globally. Its Impact Factor (IF) as measured by Thomson Reuters JCR has risen from 4.784 in 2011 to 5.168 in the 2016/2017 grading year. Between 2011 and 2016, Oncotarget’s citations have increased over 20 times from 493 to 10,452. The journal’s five-year Impact Factor stands at 5.415 as of 2015/2016 ratings. It has been given the highest ranking, Q1, by Scopus/SJR for its excellent contributions in medicine and oncology. This growing popularity informed the journal’s decision to expand the fields to be covered by the articles to be included in its publications. The fields have expanded from oncology to other fields including cell biology, pharmacology, neuroscience and cardiology. It also accepts papers on metabolism and endocrinology among other fields. Learn more about Oncotarget at Research Gate.
Journal Profile: Success Factors
Oncotarget is published weekly by Impact Journals in English. The medicine journal is peer reviewed by its highly experienced editorial board members and editors. The over a hundred editors and editorial board members are specialists in a wide range of fields including pathology, oncology, aging, immunology and microbiology, and cell biology. Some of them such as Andrew Schally are excellent research scientists who have been honored with the prestigious Nobel Prize. The excellent service delivery by the journal’s editorial board was recognized in 2013 when four members were honored with the Breakthrough Prize. These individuals have brought their experience and expertise to Oncotarget and helped the journal build a strong reputation rapidly. Others such as Mikhail Blagosklonny and Andrei V. Gudkov, who are the founding editors-in-chief, are experienced research scientists who have led cancer research for many years.
As an open access, Oncotarget accepts articles from authors around the world. It is an indication of its commitment towards knowledge and information dissemination with the view of meeting the ultimate goal of a world free from diseases. Its free access policy has also driven its popularity especially within scientific communities. Moreover, the journal’s success can also be attributed to its multidisciplinary nature. Covering numerous disciplines ensures that the journal’s impact factor and citations increase significantly. Check Oncotarget journal at scimagojr.com